Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan

Sugimoto, Toshitsugu; Inoue, Daisuke; Maehara, Masayuki; Oikawa, Ichiro; Sügimura, Takashi; Nishizawà, Yoshiki

doi:10.1007/s00774-018-0977-1

Cited by 13 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some adverse reactions of bisphosphonate for each dosing type were reported (Favus 2010), but it is not substantiated whether the dosing regimens of bisphosphonate influence the occurrence of adverse reactions. Recently, efficacy and safety of monthly doses of bisphosphonates in osteoporosis patients with mild kidney disease were reported (Sugimoto et al 2019). Finally, MPR is the accepted standard evaluation measure for medication adherence using retrospective data (Choo et al 1999;Hudson et al 2007;Ho et al 2009).…”

Section: Discussionmentioning

confidence: 99%

Adherence to Daily, Weekly, and Monthly Dosing Regimens of Bisphosphonates for Osteoporosis Treatment in Postmenopausal Women in Japan: A Retrospective Study Using Claims Data

Kosaka

Sugiyama

Hara

et al. 2021

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Poor medication adherence of osteoporosis patients is a major global medical problem because of its negative impact on health outcomes and quality of life. The aim of this study was to evaluate how differences in dosing regimens influence adherence to oral bisphosphonates using data from a large health insurance provider in Japan. This was a retrospective observational study using claims data obtained between October 2012 and January 2018, from the community-based National Health Insurance program of a large city in Japan. The data included in the analysis were obtained from women 60 to 74 years old whose oral bisphosphonate prescription was detected between April 2013 and February 2017. Treatment adherence was monitored from the initial prescription for one year, i.e., up to January 2018. Primary comparisons among the daily-dosing, weekly-dosing, and monthly-dosing groups were based on the mean medication possession ratio (MPR). Data from a total of 3,958 patients were analyzed. The numbers of patients aged 60-64, 65-69, and 70-74 were 425, 1,400, and 2,133, respectively. The highest mean MPR was 69.4% for the monthly-dosing of bisphosphonates, followed by the weekly-dosing at 63.5%, and dailydosing at 57.2%. Using the Kruskal-Wallis test with Dunn-Bonferroni correction, there were significant differences in mean MPR for daily versus weekly (p < 0.01), daily versus monthly (p < 0.001), and weekly versus monthly dosing regimens (p < 0.05). These results suggest significantly more patients adhere to a monthly or weekly regimen of bisphosphonates in the treatment of osteoporosis than to a daily regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence to Daily, Weekly, and Monthly Dosing Regimens of Bisphosphonates for Osteoporosis Treatment in Postmenopausal Women in Japan: A Retrospective Study Using Claims Data

Kosaka

Sugiyama

Hara

et al. 2021

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…To the contrary, in a meta-analysis BPs did not lower the fracture rate among kidney transplant recipients and stage 3 or 4 CKD patients [ 87 ]. In 4 Japanese placebo-controlled RCTs, risedronate had improved BMD, especially at the lumbar spine, and suppressed BTMs with similar degree of changes in patients with different stages of CKD [ 89 ]. Preclinical studies showed that BPs improved bone mass, mineralization, cortical mechanical properties, and bone strength [ 82 ].…”

Section: Pharmacological Approachmentioning

confidence: 99%

Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions – Part II

et al. 2021

View full text Add to dashboard Cite

Background: Patients with chronic kidney disease (CKD) have an increased risk of osteoporotic fractures, which is due not only to low bone volume and mass but also poor microarchitecture and tissue quality. The pharmacological and nonpharmacological interventions detailed, herein, are potential approaches to improve bone health in CKD patients. Various medications build up bone mass but also affect bone tissue quality. Antiresorptive therapies strikingly reduce bone turnover; however, they can impair bone mineralization and negatively affect the ability to repair bone microdamage and cause an increase in bone brittleness. On the other hand, some osteoporosis therapies may cause a redistribution of bone structure that may improve bone strength without noticeable effect on BMD. This may explain why some drugs can affect fracture risk disproportionately to changes in BMD. Summary: An accurate detection of the underlying bone abnormalities in CKD patients, including bone quantity and quality abnormalities, helps in institution of appropriate management strategies. Here in this part II, we are focusing on advancements in bone therapeutics that are anticipated to improve bone health and decrease mortality in CKD patients. Key Messages: Therapeutic interventions to improve bone health can potentially advance life span. Emphasis should be given to the impact of various therapeutic interventions on bone quality.

show abstract

“…4 The first choice among anti-resorptives is bisphosphonates (BPs) which are recommended for patients with early-stage of CKD (stages 1-3) having estimated glomerular filtration rate (eGFR) >45 mL min −1 with BMD scores in the osteoporotic range (T-score -2.5 or below), but are normally not recommended to patients with advanced CKD (eGFR < 35 mL min −1 ) as BPs are eliminated from the body by the kidneys. 4,5 Several trials published since 2017 show that BPs protect against bone loss in the early stages of CKD without advancing the CKD stage [6][7][8] except one that showed a significant increase in CKD progression. 5 As BPs are 100% cleared through kidneys, reservations persist among clinicians for prescribing these drugs to CKD patients.…”

Section: Introductionmentioning

confidence: 99%

Diosmin, a citrus fruit-derived phlebotonic bioflavonoid protects rats from chronic kidney disease-induced loss of bone mass and strength without deteriorating the renal function

et al. 2022

View full text Add to dashboard Cite

show abstract

Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan

Cited by 13 publications

References 33 publications

Adherence to Daily, Weekly, and Monthly Dosing Regimens of Bisphosphonates for Osteoporosis Treatment in Postmenopausal Women in Japan: A Retrospective Study Using Claims Data

Adherence to Daily, Weekly, and Monthly Dosing Regimens of Bisphosphonates for Osteoporosis Treatment in Postmenopausal Women in Japan: A Retrospective Study Using Claims Data

Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions – Part II

Diosmin, a citrus fruit-derived phlebotonic bioflavonoid protects rats from chronic kidney disease-induced loss of bone mass and strength without deteriorating the renal function

Contact Info

Product

Resources

About